At present, great interest exists in relatively small molecular weight compounds that can interact with DNA in a site-specific manner. A rapid and successful way of monitoring such interactions was achieved by reversed-phase HPLC based on DNA peak size exclusion [1] .
At present, great interest exists in relatively small molecular weight compounds that can interact with DNA in a site-specific manner. A rapid and successful way of monitoring such interactions was achieved by reversed-phase HPLC based on DNA peak size exclusion [1] .
Phenylalanine (Phe), a biogenic small molecule and an essential amino acid in humans, has been a diagnostic tool for detecting phenylketonouria, a metabolic inherited disease. On the basis of the charge and shape of Phe, we tried to measure in vitro the possible interaction of Phe with DNA by using calf thymus DNA. We also attempted a preliminary approach regarding a Phe mechanism of action on DNA by using compounds structurally related to the known antitumor antibiotic doxorubicin.
DNA binding was evaluated according to the method of Karikas et al. [1] . Calf thymus DNA was purchased from Sigma Chemical Co., and doxorubicin was from Pharmacia. HPLC-grade solvents were obtained from Lab Scan. A Hewlett-Packard HPLC series 1050 and a Lichrospher RP-18 (250 ϫ 4 mm, 5 m) were used. DNA solutions (0.1 g/L) were prepared in H 2 O and kept at 4°C. Doxorubicin (0.5 g/L) was used as a typical intercalating agent with major binding (100%) capability. l-Phe (Serva) and molecules related to l-Phe structure such as l-alanine (Serva), benzyloxycarbonyl-l-Phe, benzyloxycarbonyl-asparagine, as well as C 6 H 5 CH 2 CH(NH 2 )CH 2 NH 2 ⅐ 2HCl, were dissolved in H 2 O (each at 0.5 g/L). The column was equilibrated with a H 2 O:methanol (80:20, by vol) solution. Test samples and DNA solutions at an equivolume ratio were then introduced into the sample loop (20 L) without incubation. The flow rate was maintained at 1 mL/min, and the free DNA eluted from the column in ϳ1 min. After the appearance of DNA peak, the column was later washed with methanol for 20 min to elute the sample mixture. DNA binding is expressed as a percentage of DNA peak exclusion. All samples were tested in triplicate. Phe and doxorubicin were tested at three final concentrations (0.1, 0.25, and 0.5 g/L) vs DNA at 0.05 g/L. The results of our experiments are presented in Tables 1 and 2. As is well known, the association of cationic polyamines with negatively charged DNA induces important structural changes in DNA. Thus, spermidine and spermine can cause DNA to condense and aggregate, phenomena that have just recently been observed chromatographically [1] .
The amino acid l-alanine, which does not contain the aromatic ring of the Phe side chain because of the presence of the amino group, exhibited a measurable percentage of DNA peak exclusion. No DNA molecular effect was observed with benzyloxycarbonyl-l-Phe, which carries a protected amino group, and benzyloxycarbonyl-lasparagine, a molecule structurally related to phenylacetyl-glutamine, a metabolic product of Phe. The Phe derivative, C 6 H 5 CH 2 CH(NH 2 )CH 2 NH 2 ⅐ 2HCl, in which the carboxyl group of Phe has been replaced by an additional amino group, at 0.25 g/L showed a considerable increase of DNA peak exclusion over that caused by Phe (100% and 31.6%, respectively). This increased effect on DNA is directly related to the presence of two amino groups because DNA possesses negative charges. The latter is in full agreement with previous data [1] . The potency of the phenomenon attributed to ionic interactions is increased, when the number of amino groups increases (Table 2) . Furthermore, the ratio of DNA:ligand determines the potency of the observed DNA peak exclusion (Table 1) . Thus, we suggest that interaction of l-Phe with DNA involves its amino group (ionic interaction) as well as its aromatic ring (partial intercalation). This interaction of the aromatic group of Phe with the base-pairs of DNA is reinforced by recent findings of Burley [2] , who showed that two Phe residues of TATA box binding protein interact with the T-A basepair by Van der Waals contacts.
The observed DNA peak size exclusion in the case of doxorubicin, which contains only one ionized sugar amino group, is additional compared with Phe and related compounds (Table 1) . This is probably due to extra binding mechanisms because polyaromatic cations are known to intercalate to DNA by inserting and stacking between the base pairs at the double-helix. Furthermore, hydrogen bonding and strand breakage could also play a substantial role in this molecular multiple interaction [3] .
We suggest this simple chromatographic technique can Human serum paraoxonase (aryldialkylphosphatase, EC 3.1.8.1; PON1) and human serum platelet-activating factor acetylhydrolase (1-alkyl-2-acetyl-glycero-phosphocholine esterase, 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine acetohydrolase, EC 3.1.1.47; PAF-AH) are associated with HDL [1, 2] . PAF-AH is also found in LDL and lipoprotein(a) [Lp(a)] [3] . Recently, paraoxonase and PAF-AH have been shown to inhibit the oxidative modification of LDL [4, 5] . Furthermore, paraoxonase and PAF-AH can destroy active lipids in mildly oxidized LDL and hence may protect against the induction of inflammatory responses in arterial wall cells [6, 7] . Oxidation of LDL is recognized as a key early stage in the development of atherosclerosis, leading to uptake of LDL by the macrophage scavenger receptor and hence to formation of foam cells [8] . Thus, there is the potential for HDL-associated paraoxonase and PAF-AH to directly inhibit these processes. The PON1 gene has two common polymorphisms at amino acids 55 and 192 [9] . The 192 polymorphism leads to a Glu3 Arg substitution and results in two different isoforms that have high and low activity towards paraoxon as substrate [9, 10] . It has been suggested that paraoxonase and PAF-AH work in concert to detoxify lipid peroxides in LDL and may therefore have antiatherogenic properties [6] .
Patients with chronic renal failure are at a greatly increased risk of developing cardiovascular disease. This is only partly explained by an increased prevalence of conventional risk factors [11, 12] . Increased susceptibility of LDL to oxidation has been reported in chronic renal failure [13, 14] , although other studies have failed to confirm this finding [15, 16] . In view of the ability of HDL to protect LDL against oxidation, the aim of our study was therefore to investigate the activities of serum paraoxonase/arylesterase and PAF-AH in patients with chronic renal failure and hence to assess whether changes in activity might contribute to the accelerated development of atherosclerosis.
Blood from 72 patients receiving hemodialysis for endstage renal failure was taken after an overnight fast immediately before dialysis; the serum was separated by centrifugation at 1200g within 45 min of venipuncture and stored at Ϫ20°C until further analysis. All patients had been on regular dialysis for at least 2 months and were dialyzed either two or three times a week for 3-5 h. All were on dietary protein restriction, 1 g/kg body weight per day. Control subjects were healthy individuals on no medication. The study was performed in accordance with the guidelines of the ethics committee of The Queen's University of Belfast.
Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, apoproteins, and Lp(a) were determined by accepted methods. Total serum protein was determined with a commercial kit based on the Coomassie Blue reaction with proteins (Bio-Rad; no. 500 -006). Paraoxonase activity was determined by using two different substrates. First, the rate of hydrolysis of paraoxon was measured by monitoring the increase in absorbance at 412 nm and 25°C. The amount of p-nitrophenol generated was calculated from the molar absorptivities at pH 8.0 and pH 10.5, which were 17 000 and 18 290 L mol Ϫ1 cm Ϫ1 , respectively [17] . Paraoxonase activity is expressed in U/L serum. The assay was automated and performed on a Cobas Fara analyzer. The intraassay CV was 2.9%; the interassay CV 3.0% (n ϭ 10). Second, the paraoxonase activity was measured in an arylesterase assay with phenylacetate as substrate. The initial rate of hydrolysis (first 90 s) was recorded at 270 nm on a Hitachi U-2000 spectrophotometer [17] . Enzymatic activity was calculated from the molar absorptivity 1310 L mol Ϫ1 cm Ϫ1 . Arylesterase activity is expressed in kU/L serum. The intraassay CV was 2.9%; the interassay CV 6.5% (n ϭ 10). The paraoxonase phenotype distribution was determined by the dual-substrate method [18] , which calculates the ratio of salt-stimulated paraoxonase activity at pH 10.5 and arylesterase activity.
PAF-AH activity was determined by using 2-[acetyl-3 H]-platelet-activating factor (PAF) [19] . Serum samples were diluted 20-fold with 0.1 mol/L HEPES buffer, pH 7.2, mixed with 2-[acetyl-
3 H]PAF, and incubated for 30 min at 37°C. The [ 3 H]acetate generated after sn-2 hydrolysis was separated and quantified by liquid scintillation spectrometry. PAF-AH is expressed in U/L serum. The intraassay CV was 8.4%; the interassay CV 8.6% (n ϭ 10).
Initial analysis showed a trend for PAF-AH activity to increase with age (r ϭ 0.33, P Ͻ0.01 in the control group and r ϭ 0.24, P Ͻ0.05 in the patient group). Although there was no similar trend for paraoxonase activity, subsequent comparisons of biochemical characteristics in patients and control subjects were performed in age-and sex-matched subgroups (n ϭ 39 in each group).
The characteristics and the serum lipid and lipoprotein concentrations of patients are shown in Table 1 . HDL cholesterol, apoprotein (apo) A-I and apo A-II were found Clinical Chemistry 44, No. 1, 1998 
